Drug Trial Radar · NCT05438329
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,123
Planned (sponsor's estimate)
Start
Jul 19, 2022
Primary completion
Aug 13, 2027
Study completion Sep 10, 2027
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Jun 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
DB-1305/BNT325Drug
Administered Injection of Vein (I.V.)
PembrolizumabCombination product
Administered I.V.
BNT327Drug
Administered I.V.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.Time frame: up to 28 days after Cycle 1 Day 1
- Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
- Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
- Maximum Tolerated Dose (MTD) of DB-1305/BNT325Time frame: At the end of Cycle 1 (each cycle is up to 21 days)
- Phase 1: RP2D of DB-1305/BNT325Time frame: From first study treatment administration until the initiation of Phase 2a, approximately up to 12 months.
- Phase 2a: Percentage of Participants with TEAEs as assessed by CTCAE v5.0.Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
- Phase 2a: Percentage participants with SAEs as assessed by CTCAE v5.0.Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
- Phase 2a: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months.
Locations
93 sites in 3 countries. Site status is shown where the registry gives one.
Site 139
Bullhead City, Arizona
Site 103
Cerritos, California
Site 136
La Jolla, California
Site 127
Los Angeles, California
Site 133
Los Angeles, California
Site 108
Los Angeles, California
Site 131
Washington D.C., District of Columbia
Site 122
Coral Springs, Florida
Site 142
Hialeah, Florida
Site 114
Margate, Florida
Site 120
Miami, Florida
Site 126
Ocala, Florida
Site 140
Orange City, Florida
Site 109
Plantation, Florida
Site 141
St. Petersburg, Florida
Site 117
Tamarac, Florida
Site 111
Honolulu, Hawaii
Site 134
Chicago, Illinois
Site 124
Dearborn, Michigan
Site 106
Detroit, Michigan
Site 125
Royal Oak, Michigan
Site 129
Las Vegas, Nevada
Site 160
Mineola, New York
Site 116
New York, New York
Site 102
New York, New York
Site 130
Westbury, New York
Site 121
Wilson, North Carolina
Site 101
Canton, Ohio
Site 132
Cincinnati, Ohio
Site 118
Oklahoma City, Oklahoma
Site 123
Philadelphia, Pennsylvania
Site 112
Pittsburgh, Pennsylvania
Site 105
Nashville, Tennessee
Site 110
Arlington, Texas
Site 104
Houston, Texas
Site 115
Houston, Texas
Site 119
Tyler, Texas
Site 107
Fairfax, Virginia
Site 135
Falls Church, Virginia
Site 128
Tacoma, Washington
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.